Anebulo Pharmaceuticals (ANEB) Q2 2026 earnings summary

Executive summary

• Focused on developing selonabant, a cannabinoid receptor antagonist, for cannabis-induced toxicity, prioritizing pediatric IV formulation over adult oral product due to unmet medical need and regulatory feedback.

• Announced and completed a tender offer to repurchase shares as part of a plan to go private, with subsequent delisting and deregistration from Nasdaq and SEC reporting, effective February 27, 2026, to reduce costs and reporting burdens.

• No revenue generated to date; operations funded by equity raises, grants, and a loan facility.

Financial highlights

• Net loss for the quarter ended December 31, 2025: $2.0 million ($0.05 per share), improved from $2.5 million ($0.09 per share) in the prior year quarter.

• Net loss for the six months ended December 31, 2025: $4.2 million, improved from $4.7 million year-over-year.

• Cash and cash equivalents as of December 31, 2025: $9.0 million, with access to an additional $3.0 million via a loan agreement.

• Operating expenses for the quarter: $2.6 million, flat year-over-year.

• Grant income for the quarter: $0.6 million, up from $0.2 million in the prior year.

Outlook and guidance

• Cash and loan facility expected to fund operations for at least 12 months from the filing date.

• Research and development expenses expected to increase as clinical studies progress; general and administrative expenses expected to decrease after going private.

• Prioritizing development of selonabant IV for pediatric cannabis toxicity, aiming for a faster approval timeline than the adult oral product.

• Additional funding will be required to reach commercialization; options include equity, debt, or partnerships.

• Ongoing observational study in emergency departments is being amended to focus on pediatric patients.